Merck and MPP partner to supply paediatric HIV drug in developing nations

US-based pharmaceutical firm Merck has entered an agreement with the Medicines Patent Pool (MPP) to provide its paediatric formulations of raltegravir to treat HIV-1 infection in infants and children from four weeks to below 12 years of age in develo…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news